June 1, 2017 / 11:39 AM / 2 months ago

BRIEF-Fortress Biotech unit enters biopharmaceutical manufacturing agreement with Patheon

1 Min Read

June 1 (Reuters) - Fortress Biotech Inc:

* Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

* Fortress Biotech -unit entered a biopharmaceutical manufacturing agreement with Patheon N.V. For process development, production of cael-101​

* Fortress Biotech Inc - ‍agreement will support phase 2/3 studies of CAEL-101 for treatment of amyloid light chain ("al") amyloidosis​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below